Connect? MDS/AML Disease Registry

This is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS, ICUS or AML within 60 days prior to the date of ICF signature. Each enrolled patient will be followed for 8 years, or until early study termination, patient withdrawal or death, whichever occurs first. This study is observational and all decisions regarding patient care will be made by the treating physician. Objectives of this study is to describe the current and evolving patterns for diagnosis, prognosis, treatment, clinical monitoring and outcome measures in patients with LR or HR MDS, ICUS and AML, to compare routine clinical practice patterns with existing management guidelines, to describe treatment patterns and outcomes in patients with or without additional cytogenetic abnormalities, and to summarize patient-reported HRQoL outcomes and economic outcomes and their associations with patient characteristics, treatment regimens and clinical outcomes.